Takeda Pharmaceutical Co Ltd ADR (TAK)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NYSE
Market Cap: $68.98B
Last updated: Nov 17, 2026 at 4:37 PM ET
Takeda Pharmaceutical Co Ltd ADR (TAK) Statistics
Takeda Pharmaceutical Co Ltd ADR (TAK) has a market cap of $68.98B. It earned JPY 386.37B on revenue of JPY 4.73T over the last 12 months.
Total Valuation
| Market Cap | $68.98B |
|---|---|
| Latest price (Nov 17, 2026) | $21.64 |
Key Dates
The last ex-dividend date was Mar 31, 2026.
| Last Earnings Date | Oct 29, 2026 |
|---|---|
| Last Ex-Dividend Date | Mar 31, 2026 |
| Last Payment Date | Jul 6, 2026 |
| Fiscal Year End | March |
Valuation Ratios
Sales and book value multiples are 2.3x and 1.5x. Its year-end P/S ranged from 1.4x to 2.8x from 2016 to 2025.
| P/S Ratio | 2.3x |
|---|---|
| P/B Ratio | 1.5x |
| P/FCF Ratio | 24.5x |
Enterprise Valuation
Counting debt and cash, the company is valued at 11.5x EBITDA and 33.9x free cash flow.
| EV / EBITDA | 11.5x |
|---|---|
| EV / FCF | 33.9x |
Price Statistics
The stock is up 53.99% over 52 weeks and trades 10.80% above its 50-day average.
| Beta (1Y) | 0.04 |
|---|---|
| 52-Week Change | +53.99% |
| 1-Month Change | +10.38% |
| 3-Month Change | +18.02% |
| 6-Month Change | +30.55% |
| 5-Year Change | +49.14% |
| 10-Year Change | -6.86% |
| Total Return (1Y) | +56.18% |
| Total Return (3Y CAGR) | +19.84% |
| Total Return (5Y CAGR) | +13.23% |
| Return vs SPY (1Y) | +44.84% |
| Max Drawdown (1Y) | -19.93% |
| Max Drawdown (3Y) | -19.93% |
| Sharpe Ratio (1Y) | 2.10 |
| Correlation with SPY (1Y) | 0.03 |
| 50-Day Average | $19.53 |
| 200-Day Average | $17.76 |
| 52-Week Range | $13.48 to $21.86 |
| RSI (14 Days) | 72.5 |
| Average Volume (20 Days) | 3.03M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.15x current liabilities, and total debt is 0.62x shareholder equity.
| Current Ratio | 1.15x |
|---|---|
| Quick Ratio | 0.60x |
| Debt / Equity | 0.62x |
| Debt / EBITDA | 3.49x |
| Interest Coverage | 2.34x |
Returns and Efficiency
Return on invested capital is 5.58% over the last 12 months, against a 5-year average of 3.13%.
| Return on Equity (ROE) | 5.17% |
|---|---|
| Return on Assets (ROA) | 2.51% |
| Return on Invested Capital (ROIC) | 5.58% |
| Return on Capital Employed (ROCE) | 5.52% |
| ROE (5Y Average) | 2.12% |
| ROA (5Y Average) | 0.95% |
| ROIC (5Y Average) | 3.13% |
| Asset Turnover | 0.32x |
| Inventory Turnover | 1.34x |
| Receivables Turnover | 5.11x |
| Cash Conversion Cycle | 255 days |
Taxes
Income tax took 3.71% of pretax income over the last 12 months.
| Income Tax (TTM) | JPY 14.91B |
|---|---|
| Effective Tax Rate | 3.71% |
Scores
TAK has an Altman Z-Score of 1.40, in the distress zone below 1.81, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 1.40 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 4 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of JPY 4.73T over the last 12 months is up 7.20% from the 12 months before.
| Revenue | JPY 4.73T |
|---|---|
| Revenue Growth (YoY) | +7.20% |
| Gross Profit | JPY 2.81T |
| Operating Income | JPY 648.34B |
| Pretax Income | JPY 401.53B |
| Net Income | JPY 386.37B |
| EBITDA | JPY 1.32T |
| EBIT | JPY 699.06B |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 48.59% of the JPY 15.27T in total assets.
| Working Capital | JPY 393.61B |
|---|---|
| Shareholder Equity | JPY 7.42T |
| Tangible Book Value | JPY -1.49T |
| Total Assets | JPY 15.27T |
| Total Liabilities | JPY 7.85T |
Balance sheet as of Sep 30, 2026.
Cash Flow
After JPY 385.11B of capital spending, operating cash flow left JPY 447.47B of free cash flow.
| Operating Cash Flow | JPY 832.59B |
|---|---|
| Capital Expenditures | JPY 385.11B |
| Free Cash Flow | JPY 447.47B |
| Depreciation and Amortization | JPY 681.46B |
| Dividends Paid | JPY 315.52B |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 13.69%, against a 5-year average of 7.55%.
| Gross Margin | 59.40% |
|---|---|
| Operating Margin | 13.69% |
| Pretax Margin | 8.48% |
| Net Margin | 8.16% |
| EBITDA Margin | 27.96% |
| EBIT Margin | 14.76% |
| FCF Margin | 9.45% |
| Gross Margin (5Y Average) | 67.03% |
| Operating Margin (5Y Average) | 7.55% |
| Net Margin (5Y Average) | 3.33% |
Growth
Revenue grew 3.81% a year over 3 years.
| Revenue Growth (3Y CAGR) | +3.81% |
|---|---|
| Revenue Growth (5Y CAGR) | +7.10% |
| FCF Growth (3Y CAGR) | +22.20% |
| FCF Growth (5Y CAGR) | -4.14% |
| Operating Income Growth (3Y CAGR) | -76.68% |
Dividends and Yields
TAK pays out 18.78% of earnings as dividends.
| Dividend Per Share (Annual) | $0.63 |
|---|---|
| Dividend Yield | 2.91% |
| Dividend Growth (3Y CAGR) | -3.21% |
| Dividend Growth (5Y CAGR) | -6.78% |
| Payout Ratio | 18.78% |
| FCF Payout Ratio | 69.86% |
| FCF Yield | 4.07% |
Peer Position
Against 12 similar companies, TAK has the 9th highest P/S and the highest dividend yield.
P/S RatioPeer median 3.2x
ROICPeer median 5.03%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +5.10%
Dividend YieldPeer median 0.00%
| P/S Ratio | 2.3x vs 3.2x median |
|---|---|
| ROIC | 5.58% vs 5.03% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +7.20% vs +5.10% median |
| Dividend Yield | 2.91% vs 0.00% median |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About TAK
What is TAK's market cap?
Takeda Pharmaceutical Co Ltd ADR has a market cap of $68.98B.
How many shares of TAK are outstanding?
Takeda Pharmaceutical Co Ltd ADR has 3.21B shares outstanding. The count is up 1.73% from a year earlier.
Does TAK pay a dividend?
Yes. Takeda Pharmaceutical Co Ltd ADR pays $0.63 a share a year, a dividend yield of 2.91%.
TAK pages: Overview, Dividends, Charting, Financials, Statistics, Valuation, Competitors